Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.57 |
| ▸ | CPT2 | P23786 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28808038 | 0.82 | ACLY (0.52) | ACLYCPT2TP53HSPD1BLM | |
| SCHEMBL28995293 | 0.79 | CPT2 (0.37) | ACLYCPT2GRM2GRM3HSPD1 | |
| SCHEMBL9558578 | 0.78 | ACLY (0.57) | ACLYCPT2TP53 | |
| SCHEMBL5718547 | 0.77 | CPT2 (0.39) | ACLYCPT2 | |
| SCHEMBL9201113 | 0.77 | ACLY (0.61) | ACLYCPT2TP53HSPD1BLM | |
| SCHEMBL31390775 | 0.77 | ACLY (0.61) | ACLYCPT2TP53HSPD1BLM | |
| SCHEMBL6279850 | 0.75 | RNPEP (0.39) | ACLYCPT2GRM2GRM3HSPD1 | |
| SCHEMBL29482688 | 0.75 | ACLY (0.64) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL722576 | 0.75 | ACLY (0.64) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL28219381 | 0.74 | ACLY (0.57) | ACLYCPT2HSPD1BLMHSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1582209-B1 | THE USE OF SUCCINATE DERIVATIVE ESTERS FOR THE TREATMENT OF DEMENTIA | INST MATERIA MEDICA CAMS (CN) | 2012-09-19 | — | — | EP | disclosed |
| US-7557089-B2 | Use of derivatives of succinate esters for the treatment of dementia | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCE (CN) | 2009-07-07 | — | — | US | disclosed |
| US-20060281692-A1 | Use of derivatives of succinate esters for the treatment of dementia | BEIJING LIANXIN PHARMACEUTIC CO., LTD. (CN) | 2006-12-14 | — | — | US | disclosed |
| CN-1731991-A | Use of succinic acid derivative ester compounds for treating dementia | INST MATERIA MEDICA CAMS (CN) | 2006-02-08 | — | — | CN | disclosed |
| CN-1712057-A | Preparation of succinic acid carbobenzoxy derivative of orchid family plant effective part | DRUG INST CHINESE ACADEMY OF M (CN) | 2005-12-28 | — | — | CN | disclosed |
| EP-1582209-A1 | THE USE OF SUCCINATE DERIVATIVE ESTERS FOR THE TREATMENT OF DEMENTIA | THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2005-10-05 | — | — | EP | disclosed |
| CN-1511520-A | Use of succinate derivative for biologically treating dementia | �й�ҽѧ��ѧԺҩ���о��� | 2004-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281692-A1 | Use of derivatives of succinate esters for the treatment of dementia | BCHE, ACHE, SI | ACLY 253/4885CPT2 277/4885TP53 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.